SRPT Sarepta Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why SRPT matters now
Sarepta Therapeutics, Inc. (SRPT) is a US stock in Healthcare. The latest InvestLog snapshot shows $18.95 with -7.65% on the session and $2.00B in market capitalization; recent performance reads 1-month +5.35% and YTD -18.54%.
The latest financial table shown here is Q1 2026, with revenue of $730.8M, net income of $331.0M, and EPS of $2.88. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 5.7%.
The latest indexable market news headline is "Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout" from 24/7 Wall Street.
Additional event context on this page matters because analyst consensus is Hold with a median target of $25.00; recent insider activity includes Barry Richard filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.22
P/S
0.85
EV/EBITDA
19.39
DCF Value
$-1,365.98
FCF Yield
5.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
62.4%
Operating Margin
-1.9%
Net Margin
3.0%
ROE
4.9%
ROA
2.0%
ROIC
-1.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $730.8M | $331.0M | $2.88 |
| Q4 2025 | $442.9M | $-282.8M | $-3.93 |
| FY 2025 | $2.20B | $-713.4M | $-7.13 |
| Q3 2025 | $399.4M | $-179.9M | $-1.80 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$25.14
Target (Median)
$25.00
Target Range
$14.00 - $35.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.20
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.